Key Highlights

  • First quarter organic Revenue growth was 15.8 percent, or low double digits excluding an extra week in the fiscal calendar.
  • U.S. revenue growth accelerated to 13.1 percent from 1.5 percent in the prior quarter, driven by the MiniMed Flex pump launch in late June.
  • The company raised full year organic revenue growth guidance to approximately 10.5 percent while reaffirming adjusted EBITDA Margin guidance of approximately 16 percent.
  • MiniMed Flex received CE Mark approval ahead of schedule, with a European launch now expected in November, well ahead of the original 2027 timeline.

A strong first quarter as an independent company

MiniMed Group (NASDAQ:MMED), the Northridge, California based diabetes technology company spun off from Medtronic in March 2026, reported first quarter fiscal 2027 organic revenue growth of 15.8 percent to 843 million dollars, ahead of internal expectations. Excluding an extra week in the fiscal calendar, which contributed approximately 4.6 points of growth, underlying organic growth was in the low double digits, representing an acceleration of roughly 200 basis points from the fourth quarter of fiscal 2026.

U.S. revenue growth accelerated sharply to 13.1 percent from just 1.5 percent in the prior quarter, driven by the launch of MiniMed Flex, a smaller insulin pump roughly half the size of the company's flagship MiniMed 780G, which began shipping in late June alongside the Simplera sensor. U.S. new pumps sold grew more than 20 percent year over year, with management noting the majority of Flex sales are going to patients new to pump therapy or converting from competitive systems, both of which expand the company's installed base.

Type 2 diabetes and retention trends support the growth narrative

Approximately 40 percent of new pump starts in the United States continue to come from type 2 diabetes patients, a segment management identifies as one of the largest under-penetrated opportunities in automated insulin delivery. Real world data published on more than 6,500 type 2 patients using the company's SmartGuard algorithm showed average time in range meaningfully above American Diabetes Association guidelines without requiring meal announcements or bolusing, a differentiator management believes supports both new patient Acquisition and improving retention rates across both type 1 and type 2 cohorts.

Internationally, organic growth reached 16.9 percent, or low double digits excluding the extra week, with particular strength in Western Europe driven by tripled Simplera sensor Supply and the early rollout of the Instinct 15-day sensor, which drove pump sales up more than 50 percent in the United Kingdom in markets where it has launched. Adjusted EBITDA margin came in at 9.9 percent, below the roughly 12.2 percent underlying level after excluding approximately 230 basis points of impact from pulled-forward Investment spending and a non-operational foreign exchange remeasurement charge, both of which management characterized as timing related rather than structural.

Pipeline execution ahead of schedule, though standalone costs persist

The company disclosed several pipeline milestones achieved ahead of original timelines, including completion of the MiniMed Fit patch pump's FDA submission ahead of its fall target, with a full U.S. launch now expected by summer 2027, and completed enrollment in the pivotal trial for Vivera, its fully closed-loop algorithm, ahead of schedule. Management described MiniMed as the only company with a fully enrolled U.S. pivotal trial for a fully closed-loop algorithm, positioning Vivera as a potential category-defining upgrade path for both Flex and Fit users in the second half of calendar 2027.

Working against this positive pipeline momentum is the ongoing cost and Cash Flow burden of separating from Medtronic, with the company still working through approximately 143 remaining transition service agreements out of an original 160, and free cash flow registering a use of cash of 90 million dollars in the quarter, though this was driven almost entirely by 111 million dollars in separation-related costs. Management projected these costs will roll off over time as TSAs are exited, most within calendar 2027, but near term cash generation will likely remain distorted by standalone build-out activity until that process concludes.

A pipeline-driven growth story still normalizing post-spinoff

MiniMed's first quarter as an independent public company showed accelerating organic growth driven by genuine new product adoption rather than one-time factors, with multiple pipeline milestones achieved ahead of schedule across Flex, Fit, and Vivera. Whether this growth trajectory can be sustained probably depends on continued execution on the Fit and Vivera launches through calendar 2027, while near term cash flow and reported margins will likely remain affected by separation-related costs until the company completes its transition away from Medtronic's operational infrastructure.